晚期高级别浆液性卵巢癌延迟减瘤术中化疗中断超过10周与更差预后相关
该回顾性队列纳入205例FIGO III–IV期高级别浆液性卵巢癌行间歇性减瘤术患者,分析术前至术后化疗间隔与生存的关系。中位间隔63天,多因素分析显示肉眼残留病灶和化疗中断>10周与更差总生存相关,合并症和较长住院是化疗中断延长的独立预后因素。作者建议化疗中断应≤10周。
要点
- 化疗中断>10周与更差总生存独立相关(HR 1.65,95%CI 1.201–2.290,p=0.002)。
- 肉眼残留病灶与更差总生存相关(HR 2.280,95%CI 1.635–3.177,p≤0.001)。
- 合并症和较长住院是化疗中断延长的独立预后因素。
核心结论
- 为行间歇性减瘤术而中断化疗应≤10周,否则总生存显著受影响。
- 术前合并症患者应加强围手术期支持以尽量减少化疗中断。
研究设计与样本
- 回顾性队列研究,纳入205例FIGO III–IV期高级别浆液性卵巢癌行间歇性减瘤术患者。
- 分析术前至术后化疗间隔与无进展生存和总生存的相关性,并行单因素和多因素分析。
主要发现
- 术前至术后化疗中位间隔为63天。
- 多因素分析显示肉眼残留病灶与更差总生存相关(HR 2.280,95%CI 1.635–3.177,p≤0.001)。
- 化疗中断>10周与更差总生存相关(HR 1.65,95%CI 1.201–2.290,p=0.002)。
- 现有合并症和较长住院是化疗中断延长的独立预后因素。
关键数值与推荐
- 化疗中断>10周定义为预后不良因素,与更差总生存相关(HR 1.65,95%CI 1.201–2.290,p=0.002)。
- 肉眼残留病灶与更差总生存相关(HR 2.280,95%CI 1.635–3.177,p≤0.001)。
临床怎么用
- 对行间歇性减瘤术的高级别浆液性卵巢癌患者,应尽量将术前至术后化疗中断控制在≤10周。
- 对术前存在合并症的患者加强围手术期支持,以减少化疗中断时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The current standard of care for advanced high grade serous ovarian cancer (HGSC) comprises a combination of debulking surgery and platinum-based chemotherapy given in the neoadjuvant or adjuvant setting. In the neoadjuvant setting, patients usually undergo 3 cycles of chemotherapy followed by interval cytoreductive surgery (ICS), then 3 further cycles of chemotherapy. However, the optimum timeframe to administer chemotherapy before and after ICS remains unclear. We therefore examine the survival impact of the interval between pre- and post-operative chemotherapy in patients undergoing ICS in a well-established patient cohort. Factors leading to "delays" in recommencing post-operative chemotherapy were also examined. METHODS: The study comprises of a retrospective cohort of 205 cases with FIGO stage III and IV HGSC undergoing ICS. The duration of the interval between pre-operative and post-operative chemotherapy was correlated with progression-free (PFS) and overall survival (OS). Univariate and multivariate analyses were constructed to identify factors associated with survival and prolonged chemotherapy interruption. RESULTS: The median interval between pre-operative and post-operative chemotherapy was 63 days. Multivariate analyses revealed macroscopic residual disease (HR:2.280, 95% CI:1.635-3.177, p ≤ 0.001) and interruption of chemotherapy >10 weeks (HR:1.65, 95%CI:1.201-2.290, p = 0.002) were associated with poorer OS. Existing medical comorbidities and longer hospital stay were independent prognostic factors for prolonging the chemotherapy interruption. CONCLUSION: Our study recommends that interruption to chemotherapy to allow patients to undergo ICS should be ≤10 weeks; otherwise, OS is significantly impacted. Patients with pre-existing medical comorbidities should receive additional support pre- and post-operatively to keep the chemotherapy interruption to a minimum.
引用
- Searle G, Pounds R, Phillips A, et al. Prolonged interruption of chemotherapy in patients undergoing delayed debulking surgery for advanced high grade serous ovarian cancer is associated with a worse prognosis. Gynecol Oncol. 2020. PMID: 32345546. doi:10.1016/j.ygyno.2020.04.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。